WO2018190680A1 - NUTLINE-3α PERMETTANT DE MAÎTRISER MYCOBACTERIUM TUBERCULOSIS INTRACELLULAIRE, ET COMPOSITION ET MÉTHODE PERMETTANT DE RÉGULER L'EXPRESSION DE P53 - Google Patents
NUTLINE-3α PERMETTANT DE MAÎTRISER MYCOBACTERIUM TUBERCULOSIS INTRACELLULAIRE, ET COMPOSITION ET MÉTHODE PERMETTANT DE RÉGULER L'EXPRESSION DE P53 Download PDFInfo
- Publication number
- WO2018190680A1 WO2018190680A1 PCT/KR2018/004350 KR2018004350W WO2018190680A1 WO 2018190680 A1 WO2018190680 A1 WO 2018190680A1 KR 2018004350 W KR2018004350 W KR 2018004350W WO 2018190680 A1 WO2018190680 A1 WO 2018190680A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tuberculosis
- nutlin
- mycobacterium tuberculosis
- mycobacterium
- pharmaceutical composition
- Prior art date
Links
- 241000187479 Mycobacterium tuberculosis Species 0.000 title claims abstract description 49
- 238000000034 method Methods 0.000 title claims abstract description 12
- 230000014509 gene expression Effects 0.000 title description 16
- 230000003834 intracellular effect Effects 0.000 title description 7
- 239000000203 mixture Substances 0.000 title description 6
- 230000001276 controlling effect Effects 0.000 title 1
- 230000001105 regulatory effect Effects 0.000 title 1
- 201000008827 tuberculosis Diseases 0.000 claims abstract description 64
- 210000002540 macrophage Anatomy 0.000 claims abstract description 23
- 150000001875 compounds Chemical class 0.000 claims abstract description 15
- 239000004480 active ingredient Substances 0.000 claims abstract description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
- 230000006907 apoptotic process Effects 0.000 claims abstract description 7
- 230000001939 inductive effect Effects 0.000 claims abstract description 5
- 230000002018 overexpression Effects 0.000 claims abstract description 5
- 238000011282 treatment Methods 0.000 claims description 20
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 claims description 11
- 239000000814 tuberculostatic agent Substances 0.000 claims description 7
- 229960000285 ethambutol Drugs 0.000 claims description 6
- 229960003350 isoniazid Drugs 0.000 claims description 6
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 claims description 6
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims description 6
- 229960001225 rifampicin Drugs 0.000 claims description 6
- 229940121383 antituberculosis agent Drugs 0.000 claims description 5
- 230000001926 lymphatic effect Effects 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 206010056377 Bone tuberculosis Diseases 0.000 claims description 3
- 206010014027 Ear tuberculosis Diseases 0.000 claims description 3
- 206010015004 Epididymitis tuberculous Diseases 0.000 claims description 3
- 208000009360 Osteoarticular Tuberculosis Diseases 0.000 claims description 3
- 230000001919 adrenal effect Effects 0.000 claims description 3
- 229940072185 drug for treatment of tuberculosis Drugs 0.000 claims description 3
- 210000000959 ear middle Anatomy 0.000 claims description 3
- 201000008267 intestinal tuberculosis Diseases 0.000 claims description 3
- 208000009180 laryngeal tuberculosis Diseases 0.000 claims description 3
- 201000009671 multidrug-resistant tuberculosis Diseases 0.000 claims description 3
- 208000008128 pulmonary tuberculosis Diseases 0.000 claims description 3
- 206010038534 renal tuberculosis Diseases 0.000 claims description 3
- 201000007227 lymph node tuberculosis Diseases 0.000 claims description 2
- XEAOMHDITWFRFL-UHFFFAOYSA-N pyrazine-2-carboxamide Chemical compound NC(=O)C1=CN=CC=N1.NC(=O)C1=CN=CC=N1 XEAOMHDITWFRFL-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 15
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 230000035755 proliferation Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 11
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 description 8
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 230000001717 pathogenic effect Effects 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 7
- 241000186359 Mycobacterium Species 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- BDUHCSBCVGXTJM-WUFINQPMSA-N 4-[[(4S,5R)-4,5-bis(4-chlorophenyl)-2-(4-methoxy-2-propan-2-yloxyphenyl)-4,5-dihydroimidazol-1-yl]-oxomethyl]-2-piperazinone Chemical compound CC(C)OC1=CC(OC)=CC=C1C1=N[C@@H](C=2C=CC(Cl)=CC=2)[C@@H](C=2C=CC(Cl)=CC=2)N1C(=O)N1CC(=O)NCC1 BDUHCSBCVGXTJM-WUFINQPMSA-N 0.000 description 5
- 230000002365 anti-tubercular Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 4
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 4
- 210000004979 bone marrow derived macrophage Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 229960005206 pyrazinamide Drugs 0.000 description 4
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 102000003952 Caspase 3 Human genes 0.000 description 2
- 108090000397 Caspase 3 Proteins 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- -1 small molecule compound Chemical class 0.000 description 2
- 208000003001 spinal tuberculosis Diseases 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000034309 Bacterial disease carrier Diseases 0.000 description 1
- 102100021573 Bcl-2-binding component 3, isoforms 3/4 Human genes 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 101000971203 Homo sapiens Bcl-2-binding component 3, isoforms 1/2 Proteins 0.000 description 1
- 101000971209 Homo sapiens Bcl-2-binding component 3, isoforms 3/4 Proteins 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 241000186366 Mycobacterium bovis Species 0.000 description 1
- 241001049988 Mycobacterium tuberculosis H37Ra Species 0.000 description 1
- 241001646725 Mycobacterium tuberculosis H37Rv Species 0.000 description 1
- 108700035964 Mycobacterium tuberculosis HsaD Proteins 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229960001005 tuberculin Drugs 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
Definitions
- the present invention relates generally to the field of immunology and, in part, to methods of inhibiting survival and proliferation of Mycobacterium tuberculosis and to methods for providing Nutlin-3 ⁇ (neutrin-3 ⁇ ) and p53 expression control compositions.
- Tuberculosis is a chronic infectious disease caused by infection of Mycobacterium tuberculosis and other Mycobacterium species. Tuberculosis is a major disease in developing countries that kills about 8 million new infections each year, killing 3 million lives, and is also a problem in developed countries. While the infection may be asymptomatic for a significant period of time, tuberculosis is the most common symptom, indicating acute inflammation of the lung, resulting in fever and nonproductive cough. If left untreated, it usually results in serious complications and death.
- Tuberculosis can be treated using prolonged antibiotic therapy, but this treatment is not sufficient to prevent the spread of tuberculosis. Infected individuals do not exhibit symptoms but may be contagious for a period of time. In addition, it is difficult to control the patient's behavior even if the treatment regimen is strictly followed. Some patients do not complete the course of treatment, which can lead to ineffective treatment and development of drug resistance. Even when the entire course of treatment is completed, the TB germ infection is not eradicated from the infected individual and remains a latent infection that can still be reactivated.
- BCG Bacillus Calmette-Guerin
- PPD tuberculin proteinpurified derivative
- Antigen-specific T cell responses result in measurable degree induration at the site of infusion up to 48-72 hours post infusion, indicating exposure to mycobacterium antigens.
- the assay is problematic in sensitivity and specificity, and individuals vaccinated with BCG cannot be distinguished from those infected.
- p53 molecular weight 53 kDa
- PUMA molecular weight 53 kDa
- the P53 protein is labeled ubiquitin by MDM2 protein and degraded by proteasome.
- Nutlin-3 ⁇ (molecular weight 581.49), known as an anticancer agent, binds to this MDM2 and inhibits p53-MDM2 interaction to increase p53 pathway activity. to be. Therefore, as a method for inhibiting Mycobacterium tuberculosis with p53 as a target, Nutlin-3 ⁇ alone or in combination with existing anti-tuberculosis therapeutics may be used.
- the present invention contributes to the activation of macrophages using Nutlin-3 ⁇ , which induces expression of p53 or induces p53 activity, to provide a method for preventing and effectively treating tuberculosis, which has a different mechanism of action and relatively fewer side effects.
- the present invention is to provide a pharmaceutical composition for preventing and treating tuberculosis comprising a Nutlin-3 ⁇ compound as an active ingredient.
- the Nutlin-3 ⁇ compound thus provided is characterized by overexpressing p53, and the overexpressed p53 inhibits the growth of Mycobacterium tuberculosis by inducing apoptosis of macrophages infected with Mycobacterium tuberculosis.
- the anti-tuberculosis agent used herein may be at least one selected from the group consisting of Rifampicin, Isoniazid, Ethambutol, and Pyrazinamide.
- the present invention utilizes the function of Mycobacterium tuberculosis of Nutlin-3 ⁇ , which is not known at all, it can be expected to have a prophylactic and therapeutic effect against Mycobacterium tuberculosis having multidrug resistance with respect to existing drugs.
- the growth of latent Mycobacterium tuberculosis can be suppressed, so that latent Mycobacterium tuberculosis can be removed when used alone or in combination with a conventional medicine.
- Figure 2 is a protein expression electrophoresis picture by western blotting showing p53 expression and Caspase-3 activity according to Nutlin-3 ⁇ concentrations treated in Mycobacterium tuberculosis-infected macrophages.
- 3 is a graph showing that the number of Mycobacterium tuberculosis in macrophages is significantly reduced by Nutlin-3 ⁇ treatment.
- 4 and 5 are graphs showing that the number of Mycobacterium tuberculosis in macrophages is significantly reduced by the combination of antituberculosis therapeutic agents (isoniazid, rifampicin, pyrazinamide, ethambutol) and Nutlin-3 ⁇ .
- antituberculosis therapeutic agents isoniazid, rifampicin, pyrazinamide, ethambutol
- Nutlin-3 ⁇ are graphs showing that the number of Mycobacterium tuberculosis in macrophages is significantly reduced by the combination of antituberculosis therapeutic agents (isoniazid, rifampicin, pyrazinamide, ethambutol) and Nutlin-3 ⁇ .
- FIG. 6 is a graph showing a significant increase in Mycobacterium tuberculosis survival in mice lungs with p53-deficient macrophage.
- FIG. 7 is a graph showing that the number of Mycobacterium tuberculosis in lung tissue is significantly decreased when pneumoniae-infected mice are intraperitoneally injected with Nutlin-3a (10 mg / kg / day).
- FIG. 8 is a graph showing that the expression of p53 in the macrophage of tuberculosis patients is significantly lower than that of healthy macrophage.
- FIG. 9 is a graph showing that the number of Mycobacterium tuberculosis in cells is significantly reduced when p53 activity is increased through Nutlin-3a.
- the present invention was first identified that the Nutlin-3 ⁇ compound has an effect of preventing or treating Mycobacterium tuberculosis through p53 overexpression and acting on apoptosis of macrophages.
- the present invention comprises a Nutlin-3 ⁇ compound as an active ingredient. It is characterized by providing a composition for preventing or treating Mycobacterium tuberculosis.
- 'Nutlin-3 ⁇ ' is a small molecule compound that binds to MDM2 and inhibits binding between MDM2 and p53 protein, and is known for its anticancer effect, and its chemical structure is shown in FIG. 1. More specifically, Nutlin-3 ⁇ is a small molecule compound that binds to MDM2 and inhibits binding between MDM2 and p53 protein. It is an anticancer drug currently being developed for the treatment of solid cancer. In detail, the MDM2 protein binds to the transactivation site of p53, a gene that inhibits cancer, and blocks the activation ability. The Nutlin-3 ⁇ compound has a molecular structure similar to that of p53.
- Nutlin-3 ⁇ compound is only known as an anticancer drug that is currently being developed in the clinic, and there is no report on the effect that it has on the treatment of tuberculosis.
- the present inventors have completed the present invention by confirming that Nutlin-3 ⁇ compound can improve tuberculosis through a mechanism of activating p53.
- Example 1 of the present invention when the Nutlin-3 ⁇ compound was injected into Bone marrow-derived macrophages (BMDMs) cells, which are mouse-derived macrophages, the number of Mycobacterium tuberculosis bacteria was significantly reduced, resulting in an improvement in tuberculosis. It could be confirmed.
- BMDMs Bone marrow-derived macrophages
- Example 2 of the present invention when used in combination with the existing anti-tuberculosis agent was confirmed to show an effect of significantly higher tuberculosis bacteria compared to the use of the existing anti-tuberculosis agent alone.
- Nutlin-3 ⁇ compound is effective in improving tuberculosis
- the composition of the present invention comprising it as an active ingredient can be usefully used in the prevention or treatment for tuberculosis.
- Tuberculosis in the present invention includes eye tuberculosis, skin tuberculosis, adrenal tuberculosis, kidney tuberculosis, epididymal tuberculosis, lymphatic tuberculosis, laryngeal tuberculosis, middle ear tuberculosis, intestinal tuberculosis, multidrug-resistant tuberculosis, pulmonary tuberculosis, tuberculosis, bone tuberculosis, throat tuberculosis, lymphatic tuberculosis We can include ruins, breast tuberculosis or spinal tuberculosis.
- existing anti-tuberculosis agents may include Rifampicin, Isoniazid, Ethambutol or Pyrazinamide used in Example 2 of the present invention.
- the term 'treatment' unless stated otherwise, reverses, alleviates, inhibits, or prevents the disease or condition to which the term applies, or one or more symptoms of the disease or condition, As used herein, the term 'treatment' refers to the act of treating when 'treating' is defined as above.
- BMDMs Bone marrow-derived macrophages
- Mycobacterium tuberculosis H37Ra non-pathogenic Mycobacterium tuberculosis
- Figure 2 shows the expression level of p53 protein expressed during Mycobacterium tuberculosis infection and the apoptosis marker Caspase-3 activity as a result of Western blot method in accordance with the increased treatment concentration of Nutlin-3 ⁇ (Fig. 1), a p53 inducing agent in macrophages infected with Mycobacterium tuberculosis. Increasing p53 and Caspas-3 activity was observed. ( ⁇ -actin is an internal control in Figure 2)
- FIG. 3 was treated with Nutlin-3 ⁇ (30 uM) in large macrophages infected with Mycobacterium tuberculosis and after 24 hours, the number of viable Mycobacterium tuberculosis cells was cultured in 7H10 agar medium for 14-21 days. As a result, the number of survival of the intracellular pathogenic Mycobacterium tuberculosis and nonpathogenic Mycobacterium tuberculosis was significantly reduced in the macrophages treated with Nutlin-3 ⁇ (30 uM) compared with the control group.
- Figures 4 and 5 show anti-tuberculosis treatment of isoniazid (10 ng / ml), rifampicin (10 ng / ml), pyrazinamide (100 ng / ml) or etambutol (100 ng / ml) during the infection of Mycobacterium tuberculosis bacteria. And Nutlin-3 ⁇ (30 uM) in combination to inhibit the growth of mycobacterium tuberculosis.
- Macrophage cells infected with pathogenic Mycobacterium tuberculosis or non-pathogenic Mycobacterium tuberculosis were treated with antituberculosis treatment alone or in combination with Nutlin-3 ⁇ to determine the number of tuberculosis viable in cells after 24 hours.
- the experimental results showed that the number of intracellular tuberculosis bacteria decreased significantly when anti-TB treatment and Nutlin-3 ⁇ were used in combination with anti-TB treatment alone.
- FIG. 6 shows the number of viable Mycobacterium tuberculosis bacteria in lung tissue after intranasal infection of non-pathogenic Mycobacterium tuberculosis in a control (wild type) or macrophage-deficient p53 (p53 conditional knockout) mouse.
- wild type wild type
- macrophage-deficient p53 p53 conditional knockout
- FIG. 7 shows that the number of Mycobacterium tuberculosis in lung tissue was significantly reduced when p53 activity was increased by intraperitoneal injection of Nutlin-3a (10 mg / kg / day) into mice infected with non-pathogenic Mycobacterium tuberculosis via the nasal cavity.
- the expression of p53 in the macrophage of tuberculosis patients was significantly lower than that of healthy macrophage.
- Figure 9 was infected with non-pathogenic Mycobacterium tuberculosis in macrophage derived from the blood of healthy or tuberculosis patients, treated with Nutlin-3a (10 uM) and the number of intracellular Mycobacterium viability was measured. As a result, when the p53 activity was increased through Nutlin-3a, it was confirmed that the number of Mycobacterium tuberculosis in the cells was significantly reduced.
- the mycobacterium tuberculosis can be suppressed by increasing the expression of p53 in the cells. Therefore, when the composition according to the present invention (Nutlin-3 ⁇ ) is treated with Mycobacterium tuberculosis-infected cells as an active ingredient to control p53, that is, when the composition of the present invention is treated to Mycobacterium tuberculosis carriers, tuberculosis patients or patients with existing anti-tuberculosis drug resistance It can be expected to kill my tuberculosis bacteria.
- the statistical method used was Bonferroni's multiple comparison test, marked with * when p-value ⁇ 0.05, ** when p-value ⁇ 0.01, and *** when p-value ⁇ 0.001.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne une composition pharmaceutique permettant de prévenir ou de traiter la tuberculose, comprenant comme principe actif un composé à base de Nutline-3α. Un composé à base de Nutline-3α, qui est un principe actif selon la présente invention, a pour effet d'inhiber la prolifération de Mycobacterium tuberculosis en induisant, par l'intermédiaire de la surexpression de p53, l'apoptose des macrophages qui ont été infectés par Mycobacterium tuberculosis. Ainsi, une méthode selon la présente invention comprenant le composé à base de Nutline-3α comme principe actif peut être utilisée de manière utile pour prévenir ou traiter la tuberculose.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20170047868 | 2017-04-13 | ||
| KR10-2017-0047868 | 2017-04-13 | ||
| KR1020180041520A KR102082285B1 (ko) | 2017-04-13 | 2018-04-10 | 세포내 결핵균 제어를 위한 Nutlin-3α (뉴트린-3α) 및 p53 발현 조절 조성물 또는 방법 |
| KR10-2018-0041520 | 2018-04-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2018190680A1 true WO2018190680A1 (fr) | 2018-10-18 |
Family
ID=63793436
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/KR2018/004350 WO2018190680A1 (fr) | 2017-04-13 | 2018-04-13 | NUTLINE-3α PERMETTANT DE MAÎTRISER MYCOBACTERIUM TUBERCULOSIS INTRACELLULAIRE, ET COMPOSITION ET MÉTHODE PERMETTANT DE RÉGULER L'EXPRESSION DE P53 |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2018190680A1 (fr) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112575078A (zh) * | 2020-12-30 | 2021-03-30 | 山东大学第二医院 | lncRNAs作为活动性肺结核病特异性标志物的应用 |
| US20210379057A1 (en) * | 2018-10-16 | 2021-12-09 | Massachusetts Institute Of Technology | Nutlin-3a for use in treating a mycobacterium tuberculosis infection |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110063518A (ko) * | 2008-09-03 | 2011-06-10 | 화이자 인코포레이티드 | 결핵에 대한 병용 요법 |
| KR20140032312A (ko) * | 2012-09-06 | 2014-03-14 | 충남대학교산학협력단 | 결핵 치료용 약학적 조성물 |
| KR20150128731A (ko) * | 2013-03-15 | 2015-11-18 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 누트린-3a 및 펩티드에 의한 폐 섬유증의 저해 |
-
2018
- 2018-04-13 WO PCT/KR2018/004350 patent/WO2018190680A1/fr active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110063518A (ko) * | 2008-09-03 | 2011-06-10 | 화이자 인코포레이티드 | 결핵에 대한 병용 요법 |
| KR20140032312A (ko) * | 2012-09-06 | 2014-03-14 | 충남대학교산학협력단 | 결핵 치료용 약학적 조성물 |
| KR20150128731A (ko) * | 2013-03-15 | 2015-11-18 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 누트린-3a 및 펩티드에 의한 폐 섬유증의 저해 |
Non-Patent Citations (2)
| Title |
|---|
| CRANE, E. K.: "Nutlin-3a: A potential therapeutic opportunity for TP53 wild-type ovarian carcinomas", PLOS ONE, 2015, pages 1 - 13 * |
| MADENSPACHER, J. H.: "p53 integrates host defense and cell fate during bacterial pneumonia", THE JOURNAL OF EXPERIMENTAL MEDICINE, 2013, pages 891 - 904 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210379057A1 (en) * | 2018-10-16 | 2021-12-09 | Massachusetts Institute Of Technology | Nutlin-3a for use in treating a mycobacterium tuberculosis infection |
| CN112575078A (zh) * | 2020-12-30 | 2021-03-30 | 山东大学第二医院 | lncRNAs作为活动性肺结核病特异性标志物的应用 |
| CN112575078B (zh) * | 2020-12-30 | 2022-10-04 | 山东大学第二医院 | lncRNAs作为活动性肺结核病特异性标志物的应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bailo et al. | Lipid transport in Mycobacterium tuberculosis and its implications in virulence and drug development | |
| Estes et al. | Present and future therapeutic strategies for melioidosis and glanders | |
| Zhou et al. | Trained immunity contributes to the prevention of Mycobacterium tuberculosis infection, a novel role of autophagy | |
| Matsuo et al. | Fecal microbiota transplantation prevents Candida albicans from colonizing the gastrointestinal tract | |
| Arko‐Mensah et al. | TLR2 but not TLR4 Signalling is Critically Involved in the Inhibition of IFN‐γ‐induced Killing of Mycobacteria by Murine Macrophages | |
| Wang et al. | Baicalein resensitizes multidrug-resistant gram-negative pathogens to doxycycline | |
| WO2018190680A1 (fr) | NUTLINE-3α PERMETTANT DE MAÎTRISER MYCOBACTERIUM TUBERCULOSIS INTRACELLULAIRE, ET COMPOSITION ET MÉTHODE PERMETTANT DE RÉGULER L'EXPRESSION DE P53 | |
| Holloway et al. | Cystatins 9 and C as a novel immunotherapy treatment that protects against multidrug-resistant New Delhi metallo-beta-lactamase-1-producing Klebsiella pneumoniae | |
| J. Barton et al. | Host restriction, pathogenesis and chronic carriage of typhoidal Salmonella | |
| Matsumoto et al. | Screening for novel antituberculosis agents that are effective against multidrug resistant tuberculosis | |
| Park et al. | Understanding the reciprocal interplay between antibiotics and host immune system: how can we improve the anti-mycobacterial activity of current drugs to better control tuberculosis? | |
| Lu et al. | Antibacterial activity of an FtsZ inhibitor celastrol and its synergistic effect with vancomycin against enterococci in vitro and in vivo | |
| Wu et al. | Effects of l-Serine on Macrolide Resistance in Streptococcus suis | |
| KR102082285B1 (ko) | 세포내 결핵균 제어를 위한 Nutlin-3α (뉴트린-3α) 및 p53 발현 조절 조성물 또는 방법 | |
| KR101888101B1 (ko) | Scotin 단백질의 과발현에 의하여 결핵균 생존 및 증식을 억제하는 방법 | |
| KR102039696B1 (ko) | 세포내 결핵균 제어를 위한 p53 발현 조절 가능한 조성물 (K279-1558) 또는 방법 | |
| US10875830B2 (en) | Method of treatment | |
| KR101833460B1 (ko) | 대식세포(macrophage)의 극성(polarization)조절에 의하여 결핵균 생존 및 증식을 억제하기 위한 조성물. | |
| Mir et al. | Immunotherapeutic potential of N-formylated peptides of ESAT-6 and glutamine synthetase in experimental tuberculosis | |
| Chen et al. | Inhibitory and injury-protection effects of O-glycan on gastric epithelial cells infected with Helicobacter pylori | |
| KR101935292B1 (ko) | 대식세포의 미토콘드리아 막 단백질 mfn2의 녹다운을 이용한 결핵균 억제방법 | |
| Naamara et al. | Treating chancroid with enoxacin. | |
| Singh et al. | Tuberculosis: introduction, drug regimens, and multidrug-resistance | |
| US20200253977A1 (en) | Methods for treating amyotrophic lateral sclerosis | |
| CN111803481A (zh) | L-丙氨酸在制备预防和治疗结核药物中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18784167 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 18784167 Country of ref document: EP Kind code of ref document: A1 |